Join us on this week's episode of the Slice of Technology AI podcast, hosted by Jared S. Taylor! Our Guest: Alex Zhavoronkov, Founder & CEO at Insilico Medicine.

What you’ll get out of this episode:

• Insilico Medicine's AI-Driven Approach: Using deep learning for drug discovery, target identification, and disease modeling.

• Focus on Longevity: Alex Zhavoronkov’s mission to extend healthy human lifespan through advanced AI technologies.

• Life Models & Beyond: Development of life models using multi-modal transformers to understand aging and biology across species.

• Future of Biotech: Exploration of novel materials for sustainability and quantum computing's potential in healthcare.

Watch

Listen

Read More

Introduction

In this episode of the Slice of Technology podcast, host Jared Taylor interviews Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. With a career spanning the intersection of artificial intelligence (AI) and biotechnology, Alex shares how his company is transforming drug discovery and longevity research. Insilico Medicine uses advanced AI models to predict drug efficacy, accelerate clinical trials, and discover treatments for diseases ranging from cancer to Alzheimer’s. The company is not only changing the pharmaceutical landscape but is also focusing on sustainability and innovative materials.

The Vision for AI-Driven Drug Discovery

At the core of Insilico Medicine’s work is the integration of deep learning technology into drug discovery. Alex explains that the company uses AI to conduct disease modeling, identifying key drivers of diseases and designing molecules to target those. This innovative approach merges biological datasets and clinical trial data to predict how drugs will perform in humans. Insilico’s goal is to significantly reduce the cost and time of drug discovery, while increasing success rates.

Extending Healthy Human Lifespan

One of Alex’s lifelong goals is extending healthy human lifespan, and he describes how his research into longevity informs the company's projects. By building comprehensive life models, Insilico uses previously incompatible biological data types to create multi-modal systems that can track aging across species. These systems help in drug discovery but also provide insights into the biology of aging. Alex believes that advancements in AI will one day make it possible to extend the productive and healthy years of life.

The Future of AI, Quantum Computing, and Sustainability

Looking ahead, Alex predicts that in 20 years, AI and quantum computing will revolutionize drug discovery and material science. He discusses how Insilico is already leveraging AI to design molecules for environmental sustainability, including materials for CO2 capture and hydrogen storage. Additionally, the company envisions a future where quantum computing allows researchers to simulate entire lifetimes and worlds, accelerating the development of life-saving drugs.

HumanX and the Importance of Collaboration

In closing, Alex speaks about his excitement for the upcoming HumanX event, which brings together intellectuals and innovators from diverse fields. He emphasizes the importance of such events for sharing ideas and advancing groundbreaking research in AI, biotechnology, and beyond.

Conclusion

Insilico Medicine’s groundbreaking work at the intersection of AI and biotech is not only transforming drug discovery but also aiming to solve some of humanity’s greatest challenges. Through AI, quantum computing, and material science, Alex Zhavoronkov and his team are pushing the boundaries of what’s possible in healthcare and sustainability.

Learn More About Insilico Medicine:

Follow Us 😁